By Dan StantonBioProcess International "With cell and gene therapies coming of age, experts at Advanced Therapies Week looked to reducing COGs, novel payer models, and even biosimilars to tackle their spiraling price tags... Read entire article here: https://bioprocessintl.com/bioprocess-insider/therapeutic-class/10-cgt-approvals-in-2022-brings-gottliebs-math-close-to-realization/
